Headline Roundup September 20, 2021
Pfizer Says its COVID-19 Vaccine is Safe, Effective for Kids Ages 5-11
Summary from the AllSides News Team
On Monday, Pfizer said its COVID-19 vaccine is safe and effective for children ages 5 to 11 and that it will soon seek full approval from the Food and Drug Administration (FDA).
In Pfzier's clinical trials, it says a much lower dose was tested on children ages 5 to 11, and after the second dose, recipients developed antibody levels to fight the coronavirus that were just as strong as teenagers and young adults. The findings come as children return to school amid the spread of the contagious Delta variant, which had resulted in nearly 500,000 child COVID-19 cases between Aug. 26 and Sept. 9, according to the American Academy of Pediatrics. Children remain highly unlikely to die from COVID-19.
Featured Coverage of this Story
Pacific Press/LightRocket via Ge
Pfizer’s COVID-19 vaccine has been found to be safe and effective in children aged 5 to 11, the drugmaker said Monday.
The vaccine, created by Pfizer and German partner BioNTech, generated a “robust” immune response in young children during clinical trials, according to the company.
Pfizer now plans to use the data from the clinical trial to seek authorization from the US Food and Drug Administration and other health regulators for the 5 to 11 age group “as soon as possible”.
The vaccine is already available for anyone 12 and older in...
CNBC
A smaller dose of Pfizer and BioNTech’s Covid-19 vaccine is safe and generates a “robust” immune response in a clinical trial of kids ages 5 to 11, the drugmakers announced Monday.
The news couldn’t come any sooner for parents anxious to get their children vaccinated as kids start the new school year with the delta variant surging across America. Children’s Covid cases remain disturbingly high with 243,000 new infections during the week ended Sept. 9. — the second-highest number of kids’ cases since the beginning of the pandemic, according to the most recent data from...
CNN Digital
In a highly anticipated announcement, Pfizer said on Monday a Phase 2/3 trial showed its Covid-19 vaccine was safe and generated a "robust" antibody response in children ages 5 to 11.
These are the first such results released for this age group for a US Covid-19 vaccine, and the data has not yet been peer-reviewed or published. Pfizer said it plans to submit to the US Food and Drug Administration for emergency use authorization soon. FDA officials have said that once data is submitted, the agency could authorize a vaccine...
AllSides Picks
Blog
Media Bias Alert: DOJ Claims Biden Admin Weaponized Gov’t to ‘Chill Free Speech’ Despite Internal Dissent
Andy Gorel
October 8th, 2026
Red Blue Translator
Anti-vaxxer
Headline Roundup
Pollsters Face Obstacles as 2026 Midterms Approach
November 2nd, 2026
Blog
Villain or Hero? How the Left and Right Covered the Lone Holdout Juror in the Lindsay Clancy Trial
Jamie Krstev
November 3rd, 2026
